Structure
PT-2385, inhibitor
PT-2385
Purity
98.91%
Synonyms
PT-2385; inhibitor
Purity/Purification
98.91%
Form/Format
Solid. Powder
Solubility
DMSO: 50mg/mL (130.43mM)
:
(<1mg/ml refers to the product slightly soluble or insoluble)
:
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C17H11F3NO4S
SMILES
N#CC1=CC(F)=CC(OC2=CC=C(S(=O)(C)=O)C3=C2CC(F)(F)[C@]3O)=C1
CAS Number
1672665-49-4
Target & IC50
HIF/HIF Prolyl-Hydroxylase
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
-80 degree C for 2 years in solvent
Structure
Structure
Related Product Information for PT-2385, inhibitor
PT-2385 is a selective HIF-2alpha inhibitor (Kd<50nM).
Product Categories/Family for PT-2385, inhibitor
References
Eli Wallace, Ph.D. PT2385: HIF-2alpha Antagonist for the treatment,of VHL Mutant ccRCC. 12th International VHL Medical Symposium April 8, 2016.
Eli Wallace, Ph.D. PT2385: HIF-2alpha Antagonist for the treatment,of VHL Mutant ccRCC. 12th International VHL Medical Symposium April 8, 2016.
Xie C, et al. Activation of intestinal hypoxia-inducible factor 2alpha during obesity contributes to hepatic steatosis. Nat Med. 2017 Nov;23(11):1298-1308.
Wallace EM, et al. A Small-Molecule Antagonist of HIF2alpha Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016 Sep 15;76(18):5491-500.
Wallace EM, et al. A Small-Molecule Antagonist of HIF2alpha Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016 Sep 15;76(18):5491-500.
Eli Wallace, Ph.D. PT2385: HIF-2alpha Antagonist for the treatment,of VHL Mutant ccRCC. 12th International VHL Medical Symposium April 8, 2016.
Xie C, et al. Activation of intestinal hypoxia-inducible factor 2alpha during obesity contributes to hepatic steatosis. Nat Med. 2017 Nov;23(11):1298-1308.
Wallace EM, et al. A Small-Molecule Antagonist of HIF2alpha Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016 Sep 15;76(18):5491-500.
Wallace EM, et al. A Small-Molecule Antagonist of HIF2alpha Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016 Sep 15;76(18):5491-500.
Similar Products
Product Notes
The PT-2385 (Catalog #AAA5758711) is an Inhibitor and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "PT-2385, Inhibitor" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
